Unity Biotechnology (UBX)

Executive Summary

Unity Biotechnology was a clinical-stage biotech company that pioneered senolytic therapeutics to selectively eliminate senescent cells, targeting the underlying biology of aging. Its lead candidate, UBX1325 (foselutoclax), a Bcl-xL inhibitor, advanced into Phase 2 trials for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Early data suggested potential to improve visual outcomes and extend dosing intervals compared to standard anti-VEGF therapy. However, the company faced challenges in demonstrating robust efficacy and halted operations in 2024, terminating all programs. As a result, Unity Biotechnology no longer exists as an operating entity, and its pipeline has been completely discontinued. There are no remaining clinical trials, partnerships, or plans for further development, marking the end of its pioneering efforts in senolytic medicine.